SAPERE BIO, INC.
Biomarkers and risk stratification tools for identifying patients at high risk of developing peripheral neuropathy, with initial focus on cisplatin-induced peripheral neuropathy (CIPN) in cancer patie
- Sector
- Biotech
- Headquarters
- DURHAM, NC
- Latest Form D
- $500K, Aug 2024
- Total capital
- $4.5M
- Federal grants
- $4M
- 8 awards · 2015–2023
- Rank in peer group#20 of 42
- Private capital raised
- $500K
- 1 Form D · last Aug 2024
- 26 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 15 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$500K
- Federal grantHealth and Human S · Phase II · Measuring cellular senescence to predict and prevent peripheral neuropathy$111K
- Federal grantHealth and Human S · Phase II · Measuring cellular senescence to predict and prevent peripheral neuropathy$904K
- Federal grantHealth and Human S · Phase II · Measuring cellular senescence to predict and prevent peripheral neuropathy$915K
- Federal grantHealth and Human S · Phase II · AKI-Sapere- a novel prognostic of Acute Kidney Injury due to cardiac surgery$661K
- Federal grantHealth and Human S · Phase II · AKI-Sapere- a novel prognostic of Acute Kidney Injury due to cardiac surgery$893K
- Federal grantHealth and Human S · Phase II · AKI-Sapere- a novel prognostic of Acute Kidney Injury due to cardiac surgery$216K
Show 2 earlier federal awards
- Federal grantHealth and Human S · Phase I · Development of biomarker of aging as predictor of AKI due to cardiac surgery$75K
- Federal grantHealth and Human S · Phase I · Development of biomarker of aging as predictor of AKI due to cardiac surgery$225K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
109months
from SAPERE BIO, INC.’s first federal award to its first private round.
- First federal award · Jul 2015
- Health and Human S · $225K
- First Form D · Aug 2024
- $500K · 1st Form D
- Awards before first raise
- 8 awards
An association in public records, not a cause or a prediction.
Standing among 42 peers
Line = medianBiotech · Instrument
- Federal grants#20 · top 48%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Natalia MitinResearcherExecutive Officer, DirectorLinked by $4M in grants as PI
What it has protected
USPTO · 0 granted of 15- PendingMethods, Kits, And Systems For Modulating And Predicting Changes In P16, Senescence, And Physiological ReserveUSPTOApplication 18289605
- PendingMethods, Kits, And Systems For Predicting Patient OutcomesUSPTOApplication 18266013
- PendingMethods For Preventing Or Reducing Acute Kidney InjuryUSPTOApplication 18327967
Show all 15 patent records
- Methods, Kits, And Systems For Modulating And Predicting Changes In P16, Senescence, And Physiological ReserveJul 18, 2024 · Application 18289605Pending
- Methods, Kits, And Systems For Predicting Patient OutcomesFeb 1, 2024 · Application 18266013Pending
- Methods For Preventing Or Reducing Acute Kidney InjuryJan 11, 2024 · Application 18327967Pending
- Compositions, Methods and Kits for Stabilizing Cells and Biological SamplesApr 7, 2022 · Application 17428453Pending
- Methods For Preventing Or Reducing Acute Kidney InjuryAug 26, 2021 · Application 17151747Pending
- Methods For Preventing Or Reducing Acute Kidney InjuryJan 31, 2019 · Application 16078476Pending
- Compositions, Methods And Kits For Stabilizing Cells And Biological SamplesApplication PCTUS2020017310Pending
- Compositions, Methods and Kits for Stabilizing CellsApplication 62802684Pending
- Methods Of Guiding Treatment Using A Network Of BiomarkersApplication PCTUS2024043792Pending
- Methods Of Guiding Treatment Using A Network Of BiomarkersApplication 19513307Pending
- Methods Of Guiding Treatment Using A Network Of BiomarkersApplication 63534652Pending
- Methods, Kits, And Systems For Modulating And Predicting Changes In P16, Senescence, And Physiological ReserveApplication PCTUS2022027824Pending
- Methods, Kits, And Systems For Predicting Patient OutcomesApplication PCTUS2021062747Pending
- Methods, Kits, And Systems For Modulating And Predicting Changes In P16, Senescence, And Physiological ReserveApplication 63184897Pending
- Methods, Kits, And Systems For Predicting Patient OutcomesApplication 63123592Pending
Related companies, and why
- CERRX, INC.Similar federal contract value in Biotech · null in contracts
- CALISTOGA PHARMACEUTICALS INCSimilar federal contract value in Biotech · null in contracts
- Glycobia, Inc.Similar federal contract value in Biotech · null in contracts
- PRECISION VIROLOGICS INCSimilar federal contract value in Biotech · null in contracts
- CYTORUM, INC.Similar federal contract value in Biotech · null in contracts
- LOXAGEN INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .